BioGend Therapeutics Co., Ltd. (TPEX:6733)

BioGend Therapeutics Revenue

BioGend Therapeutics had revenue of 47.47M TWD in the quarter ending March 31, 2025, with 33.52% growth. This brings the company's revenue in the last twelve months to 179.57M, up 33.36% year-over-year. In the year 2024, BioGend Therapeutics had annual revenue of 167.65M with 52.53% growth.

• Revenue (ttm): 179.57M
• Revenue Growth: +33.36%
• P/S Ratio: 19.38
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 3.48B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	167.65M	57.74M	52.53%
Dec 31, 2023	109.91M	78.46M	249.51%
Dec 31, 2022	31.45M	22.18M	239.26%
Dec 31, 2021	9.27M	7.88M	565.40%
Dec 31, 2020	1.39M	-68.00K	-4.65%